NCT04665765

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2021-01-18Est. Completion: 2022-07-26

Enrollment target: 41 participants

Locations

City of Hope Medical Center, Duarte, California, United States
Emory University, Atlanta, Georgia, United States

Other microbiome trials you might be interested in

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.Phase 1Recruiting

Grade 3b Follicular LymphomaRecurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HLRecurrent Classic Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3a Follicular LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Transformed Non-Hodgkin LymphomaRefractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HLRefractory Classic Hodgkin LymphomaRefractory Diffuse Large B-Cell Lymphoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.